Published in J Clin Oncol on June 01, 2004
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med (2008) 1.56
Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A (2013) 1.52
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging (2014) 1.43
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res (2015) 1.23
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res (2012) 1.15
Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2015) 1.14
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res (2014) 1.08
Prostate-specific membrane antigen-based therapeutics. Adv Urol (2011) 1.06
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res (2015) 1.01
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets (2005) 1.01
New horizons in prostate cancer imaging. Eur J Radiol (2008) 0.99
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med (2010) 0.97
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics (2016) 0.94
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med (2011) 0.90
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One (2009) 0.89
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate (2009) 0.89
Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol (2008) 0.88
Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol (2011) 0.86
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med (2012) 0.85
Translational Molecular Imaging of Prostate Cancer. Curr Radiol Rep (2013) 0.82
Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One (2011) 0.80
Genomic and epigenomic alterations in prostate cancer. Front Endocrinol (Lausanne) (2012) 0.79
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol (2013) 0.79
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci (2012) 0.79
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol (2011) 0.78
Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA). PLoS One (2013) 0.76
Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels. Int J Nanomedicine (2016) 0.75
PSMA PET and Radionuclide Therapy in Prostate Cancer. Semin Nucl Med (2016) 0.75
Theragnostic ultrasound using microbubbles in the treatment of prostate cancer. Ultrasonography (2016) 0.75
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. Eur J Nucl Med Mol Imaging (2017) 0.75
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. ScientificWorldJournal (2014) 0.75
Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol (2004) 0.75
Molecular imaging and fusion targeted biopsy of the prostate. Clin Transl Imaging (2016) 0.75
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med (2002) 2.12
Clinical role of FDG PET in evaluation of cancer patients. Radiographics (2003) 2.08
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics (2004) 1.88
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol (2009) 1.80
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res (2011) 1.75
Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol (2012) 1.68
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Possible axonal regrowth in late recovery from the minimally conscious state. J Clin Invest (2006) 1.64
International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med (2013) 1.63
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 1.61
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (2003) 1.57
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell (2004) 1.57
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med (2013) 1.51
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
PET imaging of leptin biodistribution and metabolism in rodents and primates. Cell Metab (2009) 1.47
Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting. Radiographics (2011) 1.47
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res (2013) 1.46
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother Radiopharm (2004) 1.42
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol (2005) 1.38
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer (2006) 1.36
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res (2012) 1.35
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol (2003) 1.31
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med (2003) 1.26
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol (2003) 1.24
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res (2003) 1.22
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg (2010) 1.15
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer (2002) 1.14
Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedure. J Am Chem Soc (2008) 1.13
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med (2007) 1.12
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta (2004) 1.10